Nexalin Technology, Inc. 8-K

What Happened
Nexalin Technology, Inc. announced (via an 8‑K) that on January 21, 2026 it received a Nasdaq deficiency letter saying its common stock has not met the $1.00 minimum closing bid requirement under Nasdaq Listing Rule 5550(a)(2). The Company’s Nasdaq listing remains in effect for now. Nexalin issued a press release on January 23, 2026 disclosing the notice.

Key Details

• Notice date: January 21, 2026; press release: January 23, 2026.
• Requirement missed: $1.00 minimum closing bid for the last 30 consecutive business days (Nasdaq Rule 5550(a)(2)).
• Cure period: 180 calendar days to regain compliance (until July 20, 2026). To cure, the stock must close at or above $1.00 for 10 consecutive business days before that date.
• If not cured: Nasdaq may grant a second 180‑day period only if Nexalin meets market value of publicly held shares and other initial listing standards (except the minimum bid). If ultimately delisted, the Company expects its shares would trade on the OTC Markets Group.

Why It Matters
This filing signals a heightened risk that Nexalin’s shares could be moved off The Nasdaq Capital Market if the stock price doesn’t recover. While the listing is currently unaffected and the company has a defined window to regain compliance, failure to do so could reduce liquidity and investor visibility if trading shifts to the OTC market. Investors should watch the company’s closing share price and company updates through the July 20, 2026 deadline (and any Nasdaq actions or appeals).